| 1 |
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, manageꠀ ment, and prevention of chronic obstructive pulmoꠀ nary disease. Am J Respir Crit Care Med 2001;163: 1256-76
ScienceOn
|
| 2 |
Burge PS, Calverley PM, Jones PW, Spencer S, Anderꠀ son JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320: 1297-303
DOI
ScienceOn
|
| 3 |
Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, et al. A 6-month, placebocontrolled study comparing lung function and health status changes in COPD patients treated with tiotroꠀ pium or salmeterol. Chest 2002;122:47-55
DOI
ScienceOn
|
| 4 |
Lung Health Study. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obsꠀ tructive pulmonary disease. N Engl J Med 2000;343: 1902-9
DOI
PUBMED
ScienceOn
|
| 5 |
Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viꠀ skum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-23
DOI
ScienceOn
|
| 6 |
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932- 46
DOI
ScienceOn
|
| 7 |
The National Collaborating Center for Chronic Conꠀ ditions. Chronic obstructive pulmonary disease: naꠀ tional clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl I):1-232
|
| 8 |
Tashkin DP, Cooper CB. The role of long-acting broꠀ nchodilators in the management of stable COPD. Chest 2004;125:249-59
DOI
ScienceOn
|
| 9 |
Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peꠀ terson S, Olsson H. Maintenance therapy with budeꠀ sonide and formoterol in chronic obstructive pulmoꠀ nary disease. Eur Respir J 2003;22:912-9
DOI
ScienceOn
|
| 10 |
Szafranski W, Cukier A, Ramirez A, Menga G, Sanꠀ sores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21: 74-81
DOI
ScienceOn
|
| 11 |
Pauwels RA, Lofdahl C, Laitinen LS, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53
DOI
ScienceOn
|
| 12 |
Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatꠀ ment for six months with once daily tiotropium comꠀ pared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
DOI
ScienceOn
|
| 13 |
Donohue JF. Therapeutic responses in asthma and COPD: bronchodilators. Chest 2004;126:125S-37S
DOI
ScienceOn
|
| 14 |
Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-56
DOI
PUBMED
ScienceOn
|
webmaster
